Paradigm Biopharmaceuticl PBIGF

$0.01 +0.01 (643.75%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
PE ratio
—
Forward PE
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
17,600
Avg volume
51,446
Day's range
$0.01 – $0.01
Shares out
—
Stochastic %K
5%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 an...

Show more

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9629 5566
Website
https://www.paradigmbiopharma.com
Address
500 Collins Street, Level 15, Melbourne, Australia

Latest news

No headlines yet.